22
Nov
2022
Two Hard Lessons Learned from the Genocea Biosciences Experience
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Nov
2022
Team Julie: Fighting Back Against Glioblastoma
Thirty-seven years ago, I met a lovely and talented young woman while we were both pursuing our PhDs. We were married during our last year in graduate school, and have spent every day since raising a family; working in STEM-Medicine careers; and engaging with our communities. We had just retired in 2019 and begun making plans to travel and enjoy... Read More
14
Nov
2022
ICYMI – Recommended Reading and Listening for Biotech Innovators
Searching for a good listen or an interesting read? Here are my latest suggestions. Everything is awesome! Looking for something thoughtful and uplifting? A great place to start is this recent interview with tech VC Marc Andreessen, who discusses, persuasively, why he is still so optimistic about technology. Particularly useful: Andreessen’s ability to contextualize the evolution of technology, including the... Read More
7
Nov
2022
Delivery of Genetic Medicines: Shehnaaz Suliman on The Long Run
Today’s guest on The Long Run is Shehnaaz Suliman. Shehnaaz is the CEO of Menlo Park, California-based ReCode Therapeutics. Recode is working on lipid nanoparticles to improve the delivery of genetic medicines. These little packages have made it possible to deliver billions of mRNA COVID vaccines in people’s arms, saving millions of lives. It’s been two decades of hard work.... Read More
28
Oct
2022
It Ain’t Over Til It’s Over
If you’re still curious about COVID-19, then good for you. Many people apparently have stopped paying attention, but COVID-19 remains a relevant topic. Here’s where things stand this fall with viral variants and our countermeasures. We are starting a period of the Omicron epidemic in which the numbering is no longer B1, B2, B3, B4, B5. We’re into the Omicron... Read More
27
Oct
2022
Vaxcyte Takes on Pfizer, Novartis Challenges AZ, & Time Gets $100M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Oct
2022
You Have Chosen … Poorly: Why Drug Developers Make Bad Decisions
Drug development remains an incredibly expensive endeavor. Much of the cost can be attributed to late-stage clinical trial failures. The burden is borne first and foremost by clinical trial participants who aren’t helped by the experimental medicine. It also significantly impacts the companies sponsoring these studies. Everyone would like to improve the chances that a novel medicine that advances into... Read More
26
Oct
2022
Single-Cell Analysis for Precision Medicine: Tariq Kassum on The Long Run
Today’s guest on The Long Run is Tariq Kassum. Tariq is the CEO of Cambridge, Mass.-based Celsius Therapeutics. Celsius emerged on the scene in May 2018 with a $65 million Series A led by Third Rock Ventures. It was built on the conviction that single cell analysis will shed light on new targets for the treatment of cancer, autoimmunity and... Read More
26
Oct
2022
Biotech Executives Call for Action on Reproductive Health Rights
Dear Friends and Biopharma colleagues, The rapidly approaching midterm elections carry the potential to dramatically reshape the political landscape in myriad ways. The importance of the US Supreme Court’s Dobbs decision in June, overturning Roe v. Wade, looms large. At this critical time, we must be clear that Dobbs was about more than abortion. With the decision to eliminate a... Read More
26
Oct
2022
Variant Bio Strikes New Pharma Bargain, Shares Benefits of Human Genetic Research
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Oct
2022
Bezos Bets on Fred Hutch, Prime Medicine Bucks the Trend, and PacBio Throws Down
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Oct
2022
Success Should Be Celebrated. So Should Failure, Done the Right Way
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Oct
2022
A Brief History of Oligonucleotide Therapeutics
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Oct
2022
Matchpoint Gets $100M to Take Covalent Binders Into Autoimmune Disease
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Oct
2022
The Next Pandemic May Be Bacterial or Fungal. What Are We Doing to Prepare?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Oct
2022
Inflation Reduction Act: Big Changes Lurking for Drug Development
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Oct
2022
Protein Degraders For Outside the Cell: Aetna Wun Trombley on The Long Run
Today’s guest on The Long Run is Aetna Wun Trombley. Aetna is the CEO of South San Francisco-based Lycia Therapeutics. Many in biotech know about targeted protein degraders. Arvinas and Kymera Therapeutics are a couple of the well-known companies that make these drugs which work to inhibit intracellular proteins. This approach has drawn a lot of excitement because it can... Read More
11
Oct
2022
Neumora Snaps Up $112M to Advance Precision Neuroscience Work Through Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Oct
2022
Nobel for Bertozzi, Red Tree Eyes West Coast, & Doubling Down on Singapore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Oct
2022
The Kilimanjaro Climb to Fight Cancer Is Back
I’m taking another biotech team to the highest peak in Africa. Four years after the first team expedition, the Kilimanjaro Climb to Fight Cancer is back with a new crew of 28 biotech executives and investors. Together, we’re going to push ourselves physically, and raise more than $1 million for research at the Fred Hutch Cancer Center. The expedition is... Read More